LIPOPROTEIN (A) STANDARDIZATION PROGRAM

脂蛋白 (A) 标准化计划

• 批准号: 6335885
• 负责人: SANTICA M MARCOVINA
• 金额: $ 26.08万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-08-25 至 2002-08-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6335885
• 关键词: apolipoproteins; blood chemistry; blood preservation; chemical standardization; high density lipoproteins; immunologic assay /test; method development; protein purification

The measurement of lipoprotein (a) [henceforth abbreviated as Lp(a)] is of growing clinical interest because of its potential use as a strong and independent predictor for the development of coronary and cerebrovascular diseases. This association and the possible role of Lp(a) in thrombogenesis have greatly stimulated population-based studies and basic research into the genetics, structure, function, metabolism, and disease association of Lp(a). These studies have created a demand for the rapid development of commercially available immunoassays for the measurement of Lp(a) in human plasma. However, many problems have been identified with the immunochemical measurement of Lp(a) due to the complexity and heterogeneity of the protein structure of Lp(a) and the homology of apo(a) with plasminogen. There has been inadequate standardization of the various Lp(a) assays and there are no generally accepted reference materials and methods. Also, there is no consensus on how to express plasma Lp(a) values; some assays express Lp(a) as total lipoprotein mass, whereas others use total protein mass. Often there is no reference to population-based reference values. Additionally, none of the existing assays have been evaluated to establish what exactly is being measured, i.e., Lp(a), free apo(a), or apo(a) associated with triglyceride-rich lipoproteins. In addition, it has not been determined whether the antibodies employed in the assays are equally immunoreactive with all the various forms of apo(a). This contract if for the development of commercially available immunoassays for the measurement of Lp(a) in human plasma.

脂蛋白 (a) [以下缩写为 Lp(a)] 的测量为 由于其作为强效药物的潜在用途，引起了越来越多的临床兴趣 和冠状动脉疾病发展的独立预测因子 脑血管疾病。该协会及其可能发挥的作用 Lp(a)在血栓形成中的作用极大地刺激了基于人群的研究 以及遗传学、结构、功能、代谢的基础研究， Lp(a) 与疾病的关联。这些研究创造了需求 快速开发商业化免疫测定法 测量人血浆中的 Lp(a)。但也出现了很多问题 通过 Lp(a) 的免疫化学测量进行鉴定，因为 Lp(a) 的蛋白质结构的复杂性和异质性以及 apo(a) 与纤溶酶原的同源性。已经存在不足 各种 Lp(a) 测定的标准化，并且没有通用的 接受的参考材料和方法。而且也没有达成共识 关于如何表达血浆 Lp(a) 值；一些测定将 Lp(a) 表达为 总脂蛋白质量，而其他人则使用总蛋白质质量。经常 没有提及基于人口的参考值。 此外，现有的检测方法均未经过评估 确定测量的具体内容，即 Lp(a)、游离 apo(a) 或 apo(a) 与富含甘油三酯的脂蛋白相关。此外，它 尚未确定测定中是否使用了抗体 与所有不同形式的 apo(a) 具有同等的免疫反应性。这 开发商业化免疫分析的合同 用于测量人血浆中的 Lp(a)。

项目成果

Lipoprotein(a) and coronary heart disease risk.

脂蛋白（a）和冠心病风险。

• DOI: 10.1007/s11886-999-0067-z
• 发表时间: 1999
• 期刊: Current cardiology reports
• 影响因子: 3.7
• 作者: Marcovina,SM;Hegele,RA;Koschinsky,ML
• 通讯作者: Koschinsky,ML

Successful utilization of lyophilized lipoprotein(a) as a biological reagent.

成功利用冻干脂蛋白（a）作为生物试剂。

• DOI: 10.1007/s11745-004-1268-5
• 发表时间: 2004
• 期刊: Lipids
• 影响因子: 1.9
• 作者: Scanu,AngeloM;Hinman,Janet;Pfaffinger,Ditta;Edelstein,Celina
• 通讯作者: Edelstein,Celina

Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).

使用国际临床化学和实验医学联合会提出的参考材料来评估血浆脂蛋白(a)测定的分析方法。

• 发表时间: 2000
• 期刊: Clinical chemistry
• 影响因子: 9.3
• 作者: Marcovina,SM;Albers,JJ;Scanu,AM;Kennedy,H;Giaculli,F;Berg,K;Couderc,R;Dati,F;Rifai,N;Sakurabayashi,I;Tate,JR;Steinmetz,A
• 通讯作者: Steinmetz,A